Exponential Genomics (Xenomics) is building next-generation life science companies focused on combating the world’s greatest challenges—feeding, fueling, and healing humanity. Built by a team of scientists trained at Harvard and MIT, our core technology is a novel gene-editing technique capable of performing over 400 years of CRISPR in 8 weeks.
Our Xenoarray technology is well-positioned to revolutionize gene editing techniques by enabling gene knock-ins of up to 8,000 base pairs or 8 unique genes. We anticipate obtaining at least 3,000 unique cell lines from each experiment, which could radically streamline the process of integrating parallel workflows in bioengineering.
Exponential’s current commercialization projects include streamlining the manufacturing of biopharmaceuticals, vaccines, human breastmilk, cell therapies, cultured meats & dairy, water desalination, carbon recycling, cannabinoids, psychedelics, food flavors, and perfume scents.
0
Total investors
0
Early stage
0
Mid stage
0
Late stage
—
Founded
Investors
0 investors
All
Early stage
Mid stage
Late stage
No investors in this category
Frequently asked questions
What industry is Exponential Genomics, Inc. (Xenomics) in?
Exponential Genomics, Inc. (Xenomics) operates in Biotechnology. Find similar Biotechnology investors on gritt.io.
Where is Exponential Genomics, Inc. (Xenomics) based?
Exponential Genomics, Inc. (Xenomics) is headquartered in Cambridge, United States.
Find investors for your startup like Exponential Genomics, Inc. (Xenomics)
Gritt sends AI-personalised outreach to each investor — from your Gmail
